Certolizumab pegol may be an effective treatment for fatigue in patients with chronic inflammatory rheumatic diseases, according to research presented at the 2017 ACR/ARHP Annual Meeting.
Certolizumab pegol (Cimzia; UCB), a tumor necrosis factor (TNF) blocker, is currently approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA), and active ankylosing spondylitis (AS). To investigate the effect certolizumab pegol has on improving fatigue, the researchers conducted a systematic literature search for studies that included patients with rheumatic diseases who received the drug and where fatigue was assessed, using the fatigue assessment scale (FAS).
Eight studies were identified for analysis; these included 2964 patients treated with certolizumab pegol and 1056 administered placebo. The results showed that compared to the placebo arm, patients who received certolizumab pegol had experienced significant improvement with fatigue (FAS: MD = –1.50, 95% CI:–1.71 to –1.29, P <0.0001, minimum clinically important difference [MCID]: RR=2.53, 95% CI: 1.74 to 3.68).
“An improvement in the FAS score and an increase in the proportion of patients who met the MCID for FAS were observed in all the included trials regardless of the underlying disease,” the authors concluded.
For more information visit ACRabstracts.org.